Introduction {#sec1_1}
============

Adenocarcinoma, the most common type of lung cancer, accounts for nearly half of all non-small cell lung cancer (NSCLC) cases \[[@B1]\]. With more than a million deaths per year \[[@B2]\], it is the leading cause of worldwide cancer-related mortality \[[@B3]\]. A common molecular subset of NSCLC, associated with 10 and 30% of NSCLCs in North American/European and East Asian countries, respectively \[[@B4]\], harbors activating mutations in the epidermal growth factor receptor (EGFR) \[[@B5]\]. The two most common EGFR mutations are exon 19 deletions and the L858R point mutation, with exon 19 deletions leading to a longer survival following treatment with EGFR tyrosine kinase inhibitors (TKIs) compared with those with the L858R mutation \[[@B6]\].

Despite the dramatic efficacy of these TKIs, including erlotinib, gefitinib, and afatinib, in 70% of EGFR-mutant NSCLCs, the remaining 30% exhibit de novo resistance \[[@B7]\] and, even among initial responders, acquired resistance is inevitable, usually in less than 1 year \[[@B8]\].

The present report describes the case of a patient with acquired resistance to carboplatin/pemetrexed and erlotinib who demonstrated massive necrosis during treatment with the systemically nontoxic epi-immunotherapeutic agent, RRx-001 \[[@B9], [@B10], [@B11]\], in the context of a clinical trial called TRIPLE THREAT (NCT02489903). The objective of this trial is to investigate resensitization to platinum doublet chemotherapy in patients with NSCLC, SCLC, and high-grade neuroendocrine tumors.

Case {#sec1_2}
====

A 49-year-old white male US Air Force Master Sergeant and never smoker was initially diagnosed with clinical stage IIIA (T3, N1, M0) EGFR-positive (exon 19 deletion) NSCLC in June 2014 in the left upper lobe of the lung, for which he underwent upper lobectomy followed by four cycles of carboplatin (AUC = 5) and pemetrexed (500 mg/m^2^) that finished on October 29, 2014. On December 1, 2014, due to complaints of upper abdominal pain and weight loss, a metastasis to the abdomen was discovered. Surgical resection was undertaken, and pathology confirmed an EGFR-positive metastasis from the primary lung cancer.

In June 2014, a computed tomography (CT) scan demonstrated a new mass in the pancreas. Cytology samples obtained via fine needle aspiration (FNA) demonstrated the presence of an EGFR exon 19 mutation-positive lung adenocarcinoma. Treatment with erlotinib (150 mg daily) was initiated on December 22, 2014. Restaging CT 8 weeks later revealed a decreased size of the metastasis. Approximately 6 months after starting erlotinib in July 2015, restaging CT revealed disease progression. Another FNA of the mass demonstrated persistence of the EGFR exon 19 mutation.

In August 2015, the patient was enrolled on a phase II clinical trial with TH-4000 \[[@B12]\], a hypoxia-activated EGFR/Her2 inhibitor, for patients who failed erlotinib therapy. Approximately 8 weeks later, restaging CT demonstrated disease progression, with a doubling in the size of the mass.

On October 8, 2015, despite a 20-lb weight loss and a decline in performance status due to the size of the mass, he enrolled on the TRIPLE THREAT trial (NCT02489903) and received 4 mg of once weekly RRx-001. Five weeks later, due to progressively worsening abdominal pain, he was imaged with PET/CT, which demonstrated an enlarged necrotic mass in the head of the pancreas with a thin capsule of apparently viable tumor (fig. [1](#F1){ref-type="fig"}).

Image-guided aspiration of the mass yielded 200 ml of fluid, which was sent for cytology. The fluid content was positive for a predominance of necrotic debris with CD8+ T-cell infiltration. A comparison of cellularity, necrosis, and T-cell infiltrate before and after treatment with RRx-001 is demonstrated graphically in figure [2](#F2){ref-type="fig"}, and the degree of necrosis in figure [3](#F3){ref-type="fig"}.

On November 10, 2015, due to this early pseudoprogression or apparent growth of the tumor from extensive necrosis, defined as RECIST v.1.1 progression, the patient was restarted on platinum doublets (cisplatin/pemetrexed) per protocol. Since the tumor is at least partially liquefied centrally, a percutaneous drainage catheter was placed leading to significant symptomatic improvement.

Discussion {#sec1_3}
==========

While the prognosis for patients with EGFR-mutant NSCLC that have progressed on prior TKI therapy remains grim, evidence of efficacy with checkpoint inhibitors in NSCLC suggests that RRx-001, which induces antitumor immune responses, may provide a new treatment direction for NSCLC in general and EGFR-mutant NSCLC in particular, since the latter is reported to be associated with programmed death-ligand 1 (PD-L1) expression \[[@B13]\]. More detailed investigations of the functions of T and B cells and PD-1/L1 expression in the antitumor effects of RRx-001 are warranted to characterize the immune profile of these responders, which, in turn, may suggest new combination strategies to enhance the cancer immunity cycle \[[@B14]\]. As an epi-immunotherapeutic agent, RRx-001, like the DNA methyltransferase inhibitors decitabine \[[@B15]\] and azacytidine \[[@B16], [@B17]\], is associated with the production of interferon-γ \[[@B18]\]. Although, in this study, patients received RRx-001 as monotherapy, the systemic non-toxicity of RRx-001, as well as the preclinical \[[@B18]\] and preliminary clinical evidence of immune reactivation in combination with nivolumab in a phase I dose-escalation trial called PRIMETIME (NCT02518958), potentially provides a rationale for triple therapy with RRx-001, EGFR-TKIs, and anti-PD-1/PD-L1 antibodies in EGFR-mutant NSCLC.
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![Baseline FDG-PET/CT (left) demonstrating an FDG avid tumor is compared to interim FDG-PET/CT after 5 weeks of treatment with RRx-001 (right). The treatment effect is indicated by extensive central tumor necrosis with a thin halo of the apparently viable tumor.](cro-0009-0045-g01){#F1}

![Pancreatic FNA/cell block analysis. Scoring scale from 1 to 3. Cellularity scale: Ki-67 index, \<2% = 1, 2--20% = 2, and \>20% = 3. Necrosis scale: punctuate/focal = 1, geographic = 2, and widespread = 3. T-cell scale: number of CD3+ T cells per high-power field (×40), 1 = low, 2 = medium, and 3 = high.](cro-0009-0045-g02){#F2}

![Hematoxylin and eosin cell block staining before (**a**) and after therapy (**b**, 5 weeks from start of therapy) showing decreased cellular viability and a high degree of necrosis.](cro-0009-0045-g03){#F3}
